SCYNEXIS (LTS:0L49) Debt-to-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Debt-to-Asset?

SCYNEXIS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.4 Mil. SCYNEXIS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.5 Mil. SCYNEXIS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $118.3 Mil. SCYNEXIS's debt to asset for the quarter that ended in Mar. 2024 was 0.02.

SCYNEXIS Debt-to-Asset Historical Data

The historical data trend for SCYNEXIS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Debt-to-Asset Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.26

0.19

0.36

0.55

0.12

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.70	0.10	0.10	0.12	0.02

Competitive Comparison of SCYNEXIS's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Debt-to-Asset falls into.

SCYNEXIS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

SCYNEXIS's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.34	+	14.74)	/	128.412
	=	0.12

SCYNEXIS's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.356	+	2.487)	/	118.254
	=	0.02

SCYNEXIS (LTS:0L49) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

SCYNEXIS Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines